A new Japanese study also found that the frequency of adverse drug events (ADEs) such as drowsiness, hyperprolactinemia, hypersalivation, hyperlipidaemia, cognitive impairment, and Parkinsonian symptoms increased with APP compared to monotherapy [52]. Here, APP is linked to hyperprolactinemia.